FK 613

Drug Profile

FK 613

Latest Information Update: 10 Nov 2000

Price : $50

At a glance

  • Originator Fujisawa
  • Class Antiallergics; Antiasthmatics; Small molecules
  • Mechanism of Action Histamine receptor antagonists; Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Allergic rhinitis; Asthma; Urticaria

Most Recent Events

  • 10 Nov 2000 No-Development-Reported for Asthma in Japan (PO)
  • 10 Nov 2000 No-Development-Reported for Urticaria in Japan (PO)
  • 10 Nov 2000 No-Development-Reported for Allergic rhinitis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top